Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Forest Labs To Buy Clinical Data Inc.
by Ann M. Thayer
February 28, 2011
| A version of this story appeared in
Volume 89, Issue 9
Looking to acquire new products that will offset declining revenues from drugs facing patent expirations, Forest Laboratories will pay up to $1.2 billion to own the specialty pharmaceutical firm Clinical Data, based in Newton, Mass. In January, FDA approved Clinical Data’s new antidepressant Viibryd (vilazodone), which is a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist. Forest plans to launch Viibryd in the second half of 2011. According to the company, the drug is patent protected at least until March 2020.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter